In vitro and in vivo studies have revealed that NOX-A12, a novel CXCL12 inhibitor, combined with nilotinib, eliminates CML cells by inhibiting SDF1-mediated migration [58]. The gene discussed is CXCL12; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.